Background: In a phase II, open-label, multicentre Japanese study, sunitinib demonstrated antitumour activity and acceptable tolerability in metastatic renal cell carcinoma patients. Final survival analyses and updated results are reported. Methods: Fifty-one Japanese patients with a clear-cell component of metastatic renal cell carcinoma (25 treatment-naïve; 26 cytokine-refractory) received sunitinib 50 mg orally, once daily (Schedule 4/2). Overall and progression-free survivals were estimated by the KaplanMeier method. Objective response rate (per Response Evaluation Criteria in Solid Tumours) and safety were assessed with an updated follow-up. Results: First-line and pretreated patients received a median 6.0 and 9.5 treatment cycles, respectively. Investigator-assessed, end-of-study objective response rate was 52.0, 53.8 and 52.9% in first-line, pretreated and overall intent-to-treat populations, respectively. The median progression-free survival was 12.2 and 10.6 months in first-line and pretreated patients, respectively. Fourteen patients per group died (56 and 54%), and the median overall survival was 33.1 and 32.5 months, respectively. The most common treatment-related Grade 3 or 4 adverse events and laboratory abnormalities were fatigue (24%), hand-foot syndrome (18%), decreased platelet count (55%), decreased neutrophil count (53%) and increased lipase (49%). No Grade 5 treatment-related adverse events occurred. Forty patients (78%) required dose reduction, and 13 (25%) discontinued, due to treatment-related adverse events. Conclusions: With the median overall survival benefit exceeding 2.5 years, and acceptable tolerability, in first-line and pretreated Japanese metastatic renal cell carcinoma patients with Eastern Cooperative Oncology Group performance status 0/1, sunitinib showed a favourable risk/benefit profile, similar to Western studies. However, there was a trend towards greater efficacy and more haematological adverse events in Japanese patients.
INTRODUCTION
Sunitinib is an orally administered, multitargeted tyrosine kinase inhibitor of vascular endothelial growth factor (VEGF) receptors 1 -3 and platelet-derived growth factor (PDGF) receptors a and b (1) . Data from Western studies of patients with treatment-naïve and cytokine-pretreated renal cell carcinoma (RCC) have demonstrated consistent benefit with single-agent sunitinib therapy, with investigatorassessed objective response rates (ORRs) of up to 47 and 49% and median overall survival (OS) times of 26.4 and 23.9 months, for first-and second-line treatment, respectively (2 -5) .
We previously reported interim results of the first Japanese phase II study of single-agent sunitinib in 51 patients with metastatic RCC, demonstrating comparable efficacy and tolerability to that observed in Western patients (6) . In this study, the primary endpoint of ORR, based on independent review, was 48.0% in treatment-naïve patients, 46.2% among pretreated patients and 47.1% in the overall intent-to-treat (ITT) population. Median progression-free survival (PFS) was 46.0, 33.6 and 46.0 weeks (10.6, 7.8 and 10.6 months) in the same patient groups, respectively. As a result of these findings, multinational approvals of sunitinib for treatment of first-and second-line advanced RCC now include approval in Japan for patients with RCC not indicated for curative resection and patients with metastatic RCC.
Although the primary endpoint of the Japanese phase II study was met at the time of interim analysis, the median OS had not yet been reached. Here we report the final OS analysis, as well as updated efficacy and safety findings.
METHODS

PATIENTS
Patients with histologically proven RCC with a clear-cell component and metastases were included in the study. No prior systemic therapy was permitted in the first-line population, and previous treatment with only one cytokine-based regimen (that could include multiple cytokines) was permitted in the pretreated group. Additional eligibility and exclusion criteria [e.g. all patients were required to have an Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1] have been reported previously (6) .
STUDY DESIGN AND TREATMENT
This was a multicentre, open-label, non-randomized, singlearm, phase II study of sunitinib (SUTENT w ; Pfizer, New York, NY, USA) in patients with treatment-naïve or cytokine-pretreated metastatic RCC. The study was carried out in accordance with the International Conference on Harmonization Guidelines for Good Clinical Practice and was approved by the institutional review board at each participating centre. All patients provided written informed consent.
Sunitinib was administered orally at a starting dose of 50 mg once daily in the morning, without regard to meals. Treatment was given in repeated 6-week cycles consisting of 4 weeks on therapy, followed by 2 weeks off (Schedule 4/2). Intrapatient dose reductions or interruptions were permitted to manage adverse events (AEs), according to the protocol. Treatment was continued until disease progression, requirement for additional anticancer therapy, development of left ventricular systolic dysfunction or withdrawal of consent.
ASSESSMENTS
The primary endpoint was ORR in the ITT population based on independent review, and secondary endpoints included the investigator-assessed ORR, duration of response, time to tumour response, PFS, OS and safety. Tumour assessments were based on the Response Evaluation Criteria in Solid Tumours (RECIST) (7), with computed tomography or MRI scans (with or without X-rays) obtained every 6 weeks by investigators. Safety and tolerability were monitored as previously described (6) , and AEs were graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (version 3.0). A post-study survival survey was conducted once per year and included all patients who received at least one dose of sunitinib.
STATISTICAL METHODS
In the primary efficacy analysis of the ITT population, the ORR and 95% confidence intervals (CIs) were calculated based on independent review, with the same analysis performed for investigators' assessments. Sample sizes of 26 and 25 patients were required for the pretreated and first-line populations, respectively, to provide a power of 80% with an alpha level of 2.5%. These sample size calculations were based on the threshold values for response rates (5% for pretreated patients and 10% for the first-line population) considered to be clinically ineffective for each population. The efficacy of sunitinib would be confirmed if the lower limit of the 95% CI of the observed ORR was greater than or equal to the threshold rate for each population. Time-to-event endpoints were estimated using the Kaplan-Meier method (8) .
Independent review of imaging scans was discontinued after the interim analysis in February 2007 when the primary endpoint was met; therefore, only updated investigatorassessed results are reported herein.
RESULTS
PATIENT CHARACTERISTICS AND DISPOSITION
A total of 51 patients were enrolled at 12 study centres in Japan. The first-line population consisted of 25 patients with a mean age of 56.6 years (range, 33 -76), and the pretreated population comprised 26 patients with a mean age of 61.1 years (range, 34 -77). At baseline, the ECOG PS of all patients was 0 or 1, and the lung was the most prevalent site of metastases. Additional patient baseline characteristics have been described previously (6) .
All 51 patients received at least one dose of sunitinib. At the time of analysis, the first-line and pretreated groups received a median 6.0 and 9.5 treatment cycles, respectively. No patients continued to receive sunitinib after disease progression in the first-line group; however, 9/18 patients (50%) with progressive disease in the pretreated group continued to receive sunitinib after progression because of continuing benefit. Ten patients (20%) had completed the study (6 patients in the first-line group and 4 patients in the pretreated group) and 41 (80%) had discontinued (19 and 22 patients, respectively). Reasons for discontinuation included disease progression (13 patients in each group) and treatment-related AEs (6 and 7 patients, respectively, including 1 pretreated patient with a laboratory abnormality); in addition, within the pretreated group, 1 patient died and 1 patient had discontinued due to AEs unrelated to treatment.
EFFICACY
At the end of the study, the investigator-assessed ORR (95% CI) was 52.0% (31.3, 72.2) in the first-line population, 53.8% (33. 4, 73.4) in the pretreated population and 52.9% (38.5, 67.1) in the overall ITT population (Table 1 ). An additional 13 patients (6 in the first-line population and 7 in the pretreated group) had a best response of stable disease 6 weeks. The median time to tumour response was 10.0 and 10.5 weeks, and the duration of response was 25.8 and 8.8 months in the first-line and pretreated groups, respectively.
Median PFS was 12.2 months (95% CI: 7.8, 48.8) in the first-line population and 10.6 months (95% CI: 6.6, 24.2) in the pretreated population ( Figure 1 ). A total of 14 patients in each arm died (56 and 54%, respectively), and the median OS was 33.1 months (95% CI: 14.8, not reached) and 32.5 months (95% CI: 19.8 months, not reached) for the first-line and pretreated groups, respectively (Figure 2 ).
SAFETY
The most frequently reported treatment-related AEs of all grades were anorexia (72%), and skin discolouration and diarrhoea (both 64%) in the first-line population (Table 2) , and skin discolouration and fatigue (both 81%), as well as anorexia and hypertension (both 65%) in the pretreated population (Table 3) . In all patients, the majority of AEs were mild to moderate (Grades 1 or 2) in severity. Commonly reported Grade 3, treatment-related AEs in the first-line and pretreated groups, respectively, included diarrhoea (16 and 15%), fatigue (16 and 27%), hand-foot syndrome (16 and 19%) and hypertension (12 and 19%). A total of three Grade 4, treatment-related AEs were reported overall (hypomagnesaemia, dyspnoea and fatigue; all n ¼ 1), and no Grade 5 events occurred.
Laboratory abnormalities were frequently reported in both patient populations (Tables 2 and 3 ). The most common abnormalities were decreased counts for platelets (96%), white blood cells (88%), lymphocytes (84%) and neutrophils (76%) in the first-line population (Table 2 ) and decreased counts for platelets (88%), white blood cells (85%) and neutrophils (85%) and increased lipase (77%) in the pretreated population (Table 3) . Grade 3 or 4 laboratory abnormalities 1168 Japanese patients with RCC: OS with sunitinib reported in at least 50% of patients in the first-line and pretreated populations, respectively, included decreased counts for platelets (56 and 54%) and neutrophils (44 and 62%) and increased lipase (32 and 65%). Decreased lymphocyte count and increased lipase were the most frequently reported Grade 4 laboratory abnormalities in the first-line population (each n ¼ 3; 12%), while increased lipase was the most common Grade 4 abnormality in the pretreated population (n ¼ 5; 20%). No Grade 5 laboratory abnormalities were observed. The overall incidences of QT-corrected interval prolongation (n ¼ 2; 1 patient each with Grades 1 and 2 severity) and decreased left ventricular ejection fraction (LVEF; n ¼ 2; 1 patient each with Grades 2 and 3 severity) were low (both 4%) with neither condition existent at baseline. Both cases of QT-corrected interval prolongation were not clinically significant and resolved without treatment changes. One case of decreased LVEF was reported as a serious AE and resolved following treatment discontinuation.
Treatment-related AEs led to dose modifications (dose reduction or temporary discontinuation) in a total of 46 patients (90%), comprising 22 and 24 patients in the first-line and pretreated populations, respectively. Overall, the most frequent AEs leading to treatment changes were decreased counts for platelets (n ¼ 26; 51%), neutrophils (n ¼ 23; 45%) and white blood cells (n ¼ 15; 29%), as well as fatigue (n ¼ 13; 26%) and hand-foot syndrome (n ¼ 11; 22%). The majority of these events resolved, either with or without standard treatment, and did not result in sunitinib discontinuation. Discontinuation due to treatment-related AEs occurred among 13 patients (25%), and the most common AEs involved were fatigue, decreased LVEF and hypertension.
DISCUSSION
In this phase II, open-label, multicentre study of sunitinib 50 mg/day (Schedule 4/2) in Japanese patients with first-line and cytokine-refractory metastatic RCC, sunitinib showed significant antitumour activity, including a median OS benefit exceeding 2.5 years, and was generally well tolerated. The primary endpoint of ORR was met at the first interim analysis (February 2007 data cutoff ) (6) , and increased in each patient population as the study continued to produce a final ORR of 52.9% in all patients, 52.0% in the first-line population and 53.8% in the pretreated population.
Final results for the median PFS (12.2 and 10.6 months for first-line and pretreated patients, respectively) and the median OS (33.1 and 32.5 months, respectively) indicate that sunitinib provides substantial survival benefits in both treatment-naïve and cytokine-pretreated Japanese patients with metastatic RCC. Notably, the results cannot answer whether sunitinib should be used in treatment-naïve or cytokine-pretreated patients, since there may be possible differences in clinical backgrounds of each population.
Although cross-study comparisons should be interpreted with care due to methodological issues, both the median PFS and OS were longer in this study, compared with sunitinib trials in Western patients with metastatic RCC. In a recent phase III trial of first-line therapy, the median PFS was 11 months and the median OS was 26.4 months in Western patients (5) (compared with 12.2 and 33.1 months, respectively, in the present study), while, in two consecutive phase II trials of second-line therapy, the median PFS was 8.7 -8.8 months with the median OS of 23.9 months in the latter trial (3,4) (compared with 10.6 and 32.5 months, respectively, in the present study). Similarly, investigator-assessed ORRs were 5% higher in Japanese patients in this trial compared with Western patients (2 -5). Preliminary findings from an ongoing, expanded-access trial of sunitinib in patients with metastatic RCC found that efficacy was comparable between patients in Asia-Pacific and Western countries (9) . However, the expanded access trial included both treatment-naïve and pretreated patients, as well as patients from a greater geographical range than the present study, which may have affected the outcome. Finally, the .50% ORR reported in our study also compares favourably with the ORR of 14.7% reported in a phase II study of sorafenib in Japanese patients with unresectable RCC (10) .
Safety findings from the present study as well as the ongoing expanded access trial (9) indicate that the safety profile of sunitinib is generally similar in Asian and non-Asian patients. The majority of treatment-related AEs observed in this study were Grades 1 or 2 in severity, were manageable with prespecified dose changes or standard medical treatment and did not lead to study withdrawal. The previously published analysis from this study found that patients experienced modest declines in the health-related quality of life during sunitinib treatment periods, followed by recovery during subsequent off-treatment periods (6) . In combination with the AE data reported here, these results indicate that sunitinib therapy was well tolerated overall. The most frequently reported Grade 3, treatment-related AEs and laboratory abnormalities in the first-line group were diarrhoea, fatigue and hand-foot syndrome and decreased counts for platelets, neutrophils and lymphocytes, and, in the pretreated group, fatigue, hand-foot syndrome and hypertension and decreased counts for neutrophils and platelets and thrombocytopenia was 25% higher among Japanese patients in our study versus the Asian patients treated at Asian sites in the expanded access trial (9) . Grade 3 and 4 decreases in counts for neutrophils and platelets were also considerably more common in Japanese patients in the present study than in Western patients in prior studies.
At the current time, it is not clear why the tolerability and efficacy of sunitinib may differ to some extent in Japanese and Western populations. Analysis of sunitinib pharmacokinetic parameters from 13 Western studies and one Japanese study showed similar plasma exposure for sunitinib and its active metabolite SU12662 between the two populations (11), and we have previously reported a lack of correlation between sunitinib and SU12662 systemic exposure and body weight in Japanese and Caucasian subjects in an analysis that included pharmacokinetic data from the present study (6) . Further studies are needed to validate and investigate the basis of potential sunitinib tolerability and efficacy differences in these populations. In this respect, analysis of mature data from Asian and non-Asian patients in the sunitinib expanded access trial will be of interest although, there are inherent limitations to using data from such trials.
In conclusion, sunitinib 50 mg/day on Schedule 4/2 has a favourable risk/benefit profile in Japanese patients with metastatic RCC. The median OS benefit exceeded 2.5 years in both first-line and pretreated patients, in whom ECOG PS was 0 or 1, and was accompanied by acceptable tolerability. Overall, the safety and efficacy of sunitinib was similar to that reported in Western studies, although there was a trend towards greater efficacy and an increased incidence of haematological AEs in Japanese patients.
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